In the original article, there was a mistake in Figures 1, 3, 5 as published. In Figure 1A, one set of in vivo imaging pictures for Tan IIA-M and Tan IIA-H group were incorrectly used for the representative pictures, accompanying with the corresponding quantitative picture in Figure 1B. In Figure 3A, the picture for Tan IIA (5 μM) group was incorrectly used for the representative picture, accompanying with the corresponding quantitative picture in Figure 3B. In Figure 3E, the picture for Tan IIA (10 μM, 0 h) group was incorrectly used for the representative picture. In Figure 5A, the immunohistochemical picture for Snail (Tan IIA-M group) was incorrectly used for the representative picture. The corrected Figures 1, 3, 5 appear below.
FIGURE 1
Tan IIA inhibited the metastasis of colorectal cancer in vivo. (A,B) Each group of mice was injected with HCT-116/luc cells through the tail vein. After treatment with Tan IIA at concentrations of 0.5, 1, and 2 mg/kg for 4 weeks, luciferase imaging data was collected by IVIS Lumina system. ***p < 0.001, compared with control group. (C) The survival of tumor-bearing mice were evaluated, *p < 0.05; **p < 0.01; ***p < 0.001, compared with control group. (D,E) The lung tumors were excised, hemaoxylin-eosin (H,E) staining was performed and the number of metastatic lesions were counted, *p < 0.05; ***p < 0.001, compared with control group.
FIGURE 3
Tan IIA inhibited the migration of CRC cells. (A–D) HCT-116 and LoVo cells were treated with different concentration of Tan IIA, and transwell assay was used to detect the migratory cells counted from five random microscopic fields. The experiment was performed three times with similar results. *p < 0.05; **p < 0.01; **p < 0.01, compared with group without treatment of Tan IIA. (E–H) HCT-116 and LoVo cells treated with or without Tan IIA for 48 h, the wound-healing assay data were shown. The black lines were used to mark the borders of the scratches, *p < 0.05; **p < 0.01; **p < 0.01, compared with group without treatment of Tan IIA. The data were presented as the mean ± SD from at least three experiments. (I–L) The expression of MMP-2 and MMP-9 examined by Western blot, *p < 0.05; **p < 0.01; **p < 0.01, compared with group without treatment of Tan IIA. The data were from at least three experiments.
FIGURE 5
Tan IIA inhibited metastasis of CRC via β-arrestin1/β-catenin signaling pathway in vivo. (A) Immunohistochemistry on the expression of β-arrestin1, E-cadherin, Vimentin, and Snail in lung tumor tissues. (B,C) Western blot on the expression of E-cadherin, N-cadherin, Snail, and Vimentin, *p < 0.05; **p < 0.01; ***p < 0.001, compared with control group. The experiment was performed three times with similar results. (D,E) Western blot on the levels of MMP-2 and MMP-9. The data were presented as the mean ± SD from at least three experiments. **p < 0.01, compared with control group. (F,G) Western blot on the protein expression of β-arrestin1, GSK3β, β-catenin, c-Myc, and CyclinD1. *p < 0.05; **p < 0.01; ***p < 0.001, compared with control group. The data were presented from at least three experiments.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
tanshinone IIA, colorectal cancer, epithelial-to-mesenchymal transition, β-arrestin1, β-catenin signaling pathway
Citation
Song Q, Yang L, Han Z, Wu X, Li R, Zhou L, Liu N, Sui H, Cai J, Wang Y, Ji Q and Li Q (2022) Corrigendum: Tanshinone IIA Inhibits Epithelial-to-Mesenchymal Transition Through Hindering β-Arrestin1 Mediated β-Catenin Signaling Pathway in Colorectal Cancer. Front. Pharmacol. 13:929656. doi: 10.3389/fphar.2022.929656
Received
27 April 2022
Accepted
06 June 2022
Published
01 July 2022
Volume
13 - 2022
Edited and reviewed by
Yue Liu, Xiyuan Hospital, China
Updates
Copyright
© 2022 Song, Yang, Han, Wu, Li, Zhou, Liu, Sui, Cai, Wang, Ji and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Qing Ji, ttt99118@hotmail.com; Qi Li, qili@shutcm.edu.cn
†These authors have contributed equally to this work
This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.